<DOC>
	<DOC>NCT02466997</DOC>
	<brief_summary>Multicentric French parallel double-blind randomized versus placebo study</brief_summary>
	<brief_title>Efficacy of Tacrolimus in Adults With Facial Non-segmental Vitiligo - VITAC</brief_title>
	<detailed_description>Multicentric French parallel double-blind randomized versus placebo study, with duration of treatment of 6 months, and a post-treatment follow-up period of 6 months</detailed_description>
	<mesh_term>Vitiligo</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>1. Subject male or female with age over 18 years old 2. Diagnosis of nonsegmental (symmetrical) vitiligo 3. Presence of at least one vitiligo targetplaque on the face, with: Area greater than 3cm² Local Vitiligo Area Severity Index (VASI) score ≥ 50% Stable (no change in pigmentation or size over the last 3 months) Recent onset (less than 2 years duration) 4. Subject affiliated to the French social security system 1. Progressive vitiligo over the last 3 months 2. Spontaneous ongoing repigmentation (documented in the last 3 months) 3. Previous topical Tacrolimus treatment in the last 3 months 4. Previous topical or systemic treatment in the last month: Topical or oral corticosteroid Topical vitamin D Phototherapy or laser Other topical treatment specific to vitiligo Other immunosuppressant or immunomodulator 5. Underlying dermatological disease (i.e.: history of atopic dermatitis, eczema, psoriasis), which, according to the investigator, could interfere with the study assessments 6. Known sensitivity to study drug or macrolides 7. Past history of skin cancer or lymphoma 8. Congenital or acquired immunodeficiency 9. Pregnant or breastfeeding women 10. Women without contraception 11. Absence of signed informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Vitiligo</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Face</keyword>
</DOC>